Cardiac injury
Also known as: Heart, Cardiac, Cardio, Myocardium
Methodology & AI Transparency ⓘ
Cardiac injury Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Cardiac injury (also termed Heart or Cardiac) (S26.90XA; Heart & Cardiovascular Disease) utilize cardiopulmonary biomarker stratification [Cardiac injury S26.90XA] and objective NT-proBNP [Cardiac injury S26.90XA] targets (< 100 pg/mL (S26.90XA)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Synonyms for Cardiac injury (S26.90XA): Heart, Cardiac, Cardio (Heart & Vascular).
- 3 Typical cash cost range: Primary evaluation for Cardiac injury incorporates cardiopulmonary biomarker stratification [Cardiac injury S26.90XA] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Cardiac injury: maintaining NT-proBNP [Cardiac injury S26.90XA] within < 100 pg/mL (S26.90XA).
Ask our AI Specialists anything about Cardiac injury
What Is Cardiac injury?
Physicians managing Cardiac injury (also termed Heart or Cardiac) (S26.90XA; Heart & Cardiovascular Disease) utilize cardiopulmonary biomarker stratification [Cardiac injury S26.90XA] and objective NT-proBNP [Cardiac injury S26.90XA] targets (< 100 pg/mL (S26.90XA)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Cardiac injury (code S26.90XA) is subendocardial perfusion deficits [Cardiac injury S26.90XA], which Heart & Cardiovascular Disease clinicians address while surveilling NT-proBNP [Cardiac injury S26.90XA] (< 100 pg/mL (S26.90XA)).
Common Symptoms & Clinical Signs
- • Presentation of Cardiac injury (S26.90XA): reduced exercise tolerance in Cardiac injury (S26.90XA: and premature cardiovascular)
- • Secondary Cardiac injury clinical sign: exertional chest pressure in Cardiac injury (S26.90XA: or retrosternal tightness)
- • Symptom flares in Cardiac injury correlating with NT-proBNP [Cardiac injury S26.90XA] deviation outside < 100 pg/mL (S26.90XA)
- • Functional heart & vascular impact requiring cardiopulmonary biomarker stratification [Cardiac injury S26.90XA] evaluation (S26.90XA)
Cardiac injury Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | S26.90XA | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: NT-proBNP [Cardiac injury S26.90XA] | < 100 pg/mL (S26.90XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Cardiac injury S26.90XA] | < 14 ng/L (S26.90XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Cardiac injury S26.90XA] | < 70 mg/dL (S26.90XA) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cardiac injury
Treatment selection for Cardiac injury depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cardiac injury)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Editorial Expression of Concern: MicroRNA-133 controls cardiac Nature Medicine, Published online: 28 October 2026; doi:10.1038/s41591-026-04748-1 Editorial Expression of Concern: MicroRNA-133 controls cardiac hypertrophy Indexed from Nature Medicine (2026-10-28) by DotMD's 2-hour clinical... Nature Medicine • 2026-10-28 • Peer-Reviewed Journal (Longevity & Biotech) | Multi-cohort | 97/100 | PMID NATURE_MED-3271351927 ↗ |
| New Insights on Naloxegol on transit recovery in patients undergoing cardiac surgery: A: What a 299-Participant Study Found Naloxegol was not found to be effective in improving the transit time recovery after elective cardiac surgery. Anaesthesia, critical care & pain medicine • 2025-04-15 • Phase III Randomized Trial | N = 299 | 93/100 | PMID 39988233 ↗ |
| What the Latest Evidence Really Says About Statin and Postcardiac Surgery irregular heartbeat (AFib) No statistically significant difference between statin pretreatment and placebo (OR 0.87; 95% CI: 0.71-1.07, P = 0.18) as well as for atorvastatin (OR 0.88; 95% CI: 0.61-1.28; P = 0.48; I 2 = 84%) and rosuvastatin (OR 0.87;... Journal of cardiovascular pharmacology • 2022-08-01 • Meta-Analysis | Multi-cohort | 92/100 | PMID 35580320 ↗ |
| New Insights on Association of predicted lean muscle and fat mass with prognosis in patients with: What a 3,320-Participant Study Found In patients with HFpEF, a higher FMI was strongly associated with increased risks of both the primary endpoint and all-cause mortality, while an elevated LBMI was associated with a reduced risk of mortality. PloS one • 2025-01-15 • Phase III Randomized Trial | N = 3,320 | 90/100 | PMID 40446077 ↗ |
| New Insights on Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic: What a 5,250-Participant Study Found History of CHD, history of stroke and age were the only significant predictors of cardiac morbidity in patients with new-onset diabetes. Blood pressure • 2016-08-15 • Randomized Controlled Trial | N = 5,250 | 90/100 | PMID 26808585 ↗ |
Cardiac injury Patient Community & “People Like Me” Threads
Filter Cardiac injury community threads and patient logs by age, biological sex, dosage, and treatment duration.